Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discu ...

Emcure Pharmaceuticals posted a 35.4 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at Rs 153.7 crore ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Read on to learn more about the six Australian and New Zealand startups that raised $234.2 million in the legal, healthcare ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

But now, thanks to a combination of non-profit researchers and African public-health workers, there are signs of progress ...

Pennsylvania’s universities - Pitt, UPenn and Penn State in particular - have big reputations, and to back them up, they ...

Bioethics, a modern academic field that helps resolve such fraught dilemmas, evolved in its early decades through debates ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target ...